stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) EBITDA
Replimune Group, Inc.'s EBITDA for fiscal 2026 was −$319.1M, compared with −$267.1M in fiscal 2025. Over the twelve months to 30 September 2026 it was −$266.7M. Over the past ten years it has ranged from −$319.1M (fiscal 2026) to −$9.5M (fiscal 2017) — the current reading is the lowest in ten years. EBITDA has fallen for 9 consecutive fiscal years. Replimune Group, Inc. ranks 544th of 596 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | −$319.1M | — |
| FY2025 | −$267.1M | — |
| FY2024 | −$244.4M | — |
| FY2023 | −$180.3M | — |
| FY2022 | −$113.9M | — |
| FY2021 | −$76.9M | — |
| FY2020 | −$56.6M | — |
| FY2019 | −$32.5M | — |
| FY2018 | −$19.2M | — |
| FY2017 | −$9.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$54.5M | — |
| Jun 2026 | −$66.6M | — |
| Mar 2026 | −$72.9M | — |
| Dec 2025 | −$72.7M | — |
| 34 more quarters | Free account |
Against its own ten years
Low −$319.1M
High −$9.5M
Ten-year median
−$95.4M
Current reading's percentile
10
EBITDA against peers
| Company | EBITDA |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| ZYME Zymeworks Inc. compare | $53.8M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. compare | −$198.6M |
| REPL Replimune Group, Inc. | −$266.7M |
| IMNM Immunome, Inc. compare | −$298.0M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item